Total Funding
41
11
Total FundingGrant raised
Growth Score 41 in past quarter
-2 pts
Heat Score 11 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
377938
NanoHybrids harnesses the power of nanotechnology and molecular targeting.
Konstantin Sokolov: Founder
Paul McCormick: CEOPast Role: Cardiogenesis Corporation, Chairman/Executive Chairman
About the Company
As nanotechnology rapidly expands into the realms of medicine, there is an unmet need for “smart” nanoparticles capable of homing in on diseased tissue while leaving healthy cells intact. When targeted to specific biomarkers, these nanoparticles can provide critical information about the biology of the disease in the context of the anatomy both in
vitro and in vivo.
Their nano-sized contrast agents can enhance biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. Their products can potentially be employed in a wide variety of applications including optical biomedical imaging, microscopy, molecular diagnostics and theranostic approaches.
Women Founded

